Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -- Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on...
- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - ...
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini...
Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial. Treatment with the drug candidate, acquired as part of the purchase of U.S. biotech firm Chinook Therapeutics for up to $3.5 billion, resulted in a clinically meaningful improvement in kidney filtration in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement.